Inclusion Criteria:

          1. Unresectable hepatocellular carcinoma and at intermediate-stage HCC (BCLC stage B or
             Child-Pugh class A/B with large or multifocal HCC, no vascular invasion, or
             extrahepatic spread) with completed TACE procedure in 4 weeks before day 1 of study
             intervention infusion.

          2. Recovered from TACE treatment and procedure related toxicities including ALT/AST and
             bilirubin within normal limit or reference numeric value (reference value is defined
             as the test value before TACE procedure).

          3. ECOG (Eastern Cooperative Oncology Group) performance status < 2.

          4. Have adequate organ and marrow function as defined below:

               1. Absolute neutrophil count > 1,200/µL

               2. Hemoglobin > 9 g/dL

               3. Platelets > 100,000/µL

               4. Total bilirubin < 2 X ULN

          5. Have adequate kidney function as estimated glomerular filtration rate (eGFR) > 60
             mL/min/1.73m2

          6. A negative pregnancy test at screening. This applies to any female patient with
             childbearing potential.

          7. Agree to use adequate contraception after signing informed consent form, during the
             duration of study participation and for at least 4-weeks after completion or
             withdrawal from the study. This applies to any female patient with childbearing
             potential and any male patient whose female partner has childbearing potential.

             Acceptable contraceptive methods include:

               1. Established use of oral, injected or implanted hormonal methods of contraception

               2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)

               3. Barrier methods of contraception: condom or occlusive cap (diaphragm or
                  cervical/vault caps) >=20 years of age. (Note: In Taiwan, age of majority
                  recognized in law is 20 years of age)

          8. >=20 years of age. (Note: In Taiwan, age of majority recognized in law is 20 years of
             age)

          9. Anticipated life expectancy of >= 6 months at assessment during screening.

         10. Ability to understand and have signed a written informed consent document.

        Exclusion Criteria:

          1. 1. Patient with Child-Pugh B8-9.

          2. Patient who has had anti-cancer therapy including surgery, radiotherapy,
             immunotherapy, or chemotherapy (except in TACE regimen) within 4 weeks prior to the
             screening visit.

          3. Patient who has received any other investigational agents within 4 weeks prior to the
             screening visit.

          4. Patient who has not recovered from the side effects of the earlier investigational
             agent or had anti-cancer therapy including surgery, radiotherapy, immunotherapy, or
             chemotherapy.

          5. Patient with known brain metastases, leptomeningeal or epidural metastases (unless
             treated and well controlled for >= 3 months).

          6. Patient with prior history of co-malignancies, except for adequately treated carcinoma
             in situ of the cervix, ductal carcinoma in situ (DCIS) of the breast, and basal
             cell/squamous cell skin cancer.

          7. Patient with history of myocardial infarction or uncontrolled cardiac dysfunction, or
             unstable arrhythmia or symptomatic peripheral arterial vascular disease.

          8. Patient with history of positive serology for human immunodeficiency virus (HIV).

          9. Patient with active, uncontrolled bacterial, viral, or fungal infections, which
             require systemic therapy.

         10. Patient with poor liver function as indicated by serum bilirubin > 2 mg/dL, Child-Pugh
             Class C, severe coagulopathy (INR > 2) not correctable with vitamin K, or active
             hepatic encephalopathy.

         11. Patient with known allergic reactions to biological agent or polypeptides similar to
             PTX-9908 Injection.

         12. Woman who is pregnant or nursing.

         13. Patient with concomitant disease or condition that could interfere with the conduct of
             the study, or that would, in the opinion of the investigator, pose an unacceptable
             risk to the patient in this study.

         14. Patient with unwillingness or inability to comply with the study protocol for any
             reason.

         15. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval >480 milliseconds (ms) (CTCAE grade 1) using Frederica's QT correction
             formula

         16. A history of additional risk factors for torsades de pointes (e.g., heart failure,
             hypokalemia, family history of Long QT Syndrome)

         17. The use of concomitant medications that prolong the QT/QTc interval